Drugs / NXT007
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06189508 | Feb → Dec 2024 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05987449 | Sep 2023 → Dec 2033 expected | hemophilia A | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07838194 | Nov 2026 → Sep 2028 expected | hemophilia A | Hoffmann-La Roche | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07416526 | May 2026 → Sep 2027 expected | hemophilia A | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 3 | NCT07416604 | Apr 2026 → Feb 2028 expected | hemophilia A | Hoffmann-La Roche | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2026-02-09 | Chugai Pharmaceutical | Results NXT007 Suggests Favorable Tolerability and Efficacy in Phase I/II Study for Hemophilia A Following Direct Switch from Emicizumab without Washout Period chugai-pharm.co.jp ↗
Similar to Part B in emicizumab-naïve participants, the highest-dose cohorts achieved plasma concentrations expected to provide factor VIII activity within the normal range, with no bleeds requiring treatment |
| 2025-11-03 | Hoffmann-La Roche | Results Roche to present new data from its broad and innovative haematology portfolio at ASH 2025 roche.com ↗
Positive phase I/II results, including new data from a global study in people with haemophilia A with and without factor VIII inhibitors, suggest the potential of Roche’s next-generation investigational bispecific antibody to normalise haemostasis. |
| 2025-11-03 | Genentech, Inc. | Results Genentech to Present New Data From Its Broad and Innovative Hematology Portfolio at ASH 2025 gene.com ↗
Positive Phase I/II results, including new data from a global study in people with hemophilia A with and without factor VIII inhibitors, suggest the potential of Genentech’s next-generation investigational bispecific antibody to normalize hemostasis. |
| 2025-06-23 | Hoffmann-La Roche | Results Early data suggest Roche’s NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A roche.com ↗
In presented data from the primary analysis, no treated bleeds were observed with NXT007 in the highest dose cohorts (B-3 and B-4). |
| 2025-06-23 | Chugai Pharmaceutical | Results Phase I/II Study in Hemophilia A Suggests NXT007 May Have the Potential to Provide Hemostatic Normalization chugai-pharm.co.jp ↗
We are very excited that this first data in people with hemophilia A, suggests that NXT007 has the potential to provide hemostatic normalization. |
| 2023-11-07 | Chugai Pharmaceutical | Results Non-Clinical Research Results of Chugai’s NXT007 Published in Journal of Thrombosis and Haemostasis chugai-pharm.co.jp ↗
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that the results of non-clinical research on NXT007, have been published in the online version of the Journal of Thrombosis and Haemostasis (JTH). |
All press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-02-09 | Chugai Pharmaceutical | NXT007 Suggests Favorable Tolerability and Efficacy in Phase I/II Study for Hemophilia A Following Direct Switch from Emicizumab without Washout Period chugai-pharm.co.jp ↗ |
| 2025-11-03 | Hoffmann-La Roche | Roche to present new data from its broad and innovative haematology portfolio at ASH 2025 roche.com ↗ |
| 2025-11-03 | Genentech, Inc. | Genentech to Present New Data From Its Broad and Innovative Hematology Portfolio at ASH 2025 gene.com ↗ |
| 2025-06-23 | Hoffmann-La Roche | Early data suggest Roche’s NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A roche.com ↗ |
| 2025-06-23 | Chugai Pharmaceutical | Phase I/II Study in Hemophilia A Suggests NXT007 May Have the Potential to Provide Hemostatic Normalization chugai-pharm.co.jp ↗ |
| 2023-11-07 | Chugai Pharmaceutical | Non-Clinical Research Results of Chugai’s NXT007 Published in Journal of Thrombosis and Haemostasis chugai-pharm.co.jp ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NXT007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05987449 ↗ |
| Route | Subcutaneous | “NXT007 administered subcutaneously (SC)” NCT05987449 ↗ |